These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 37290639)

  • 1. CRISPR-Cas9 in Alzheimer's disease: Therapeutic trends, modalities, and challenges.
    Chacko L; Chaudhary A; Singh B; Dewanjee S; Kandimalla R
    Drug Discov Today; 2023 Aug; 28(8):103652. PubMed ID: 37290639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9 Gene Editing: A Novel Approach Towards Alzheimer's Disease Treatment.
    Tripathi S; Sharma Y; Rane R; Kumar D
    CNS Neurol Disord Drug Targets; 2024; 23(12):1405-1424. PubMed ID: 38716549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics.
    Bhardwaj S; Kesari KK; Rachamalla M; Mani S; Ashraf GM; Jha SK; Kumar P; Ambasta RK; Dureja H; Devkota HP; Gupta G; Chellappan DK; Singh SK; Dua K; Ruokolainen J; Kamal MA; Ojha S; Jha NK
    J Adv Res; 2022 Sep; 40():207-221. PubMed ID: 36100328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications.
    Li Y; Glass Z; Huang M; Chen ZY; Xu Q
    Biomaterials; 2020 Mar; 234():119711. PubMed ID: 31945616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in therapeutic application of CRISPR-Cas9.
    Sun J; Wang J; Zheng D; Hu X
    Brief Funct Genomics; 2020 May; 19(3):164-174. PubMed ID: 31769791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9 therapeutics: progress and prospects.
    Li T; Yang Y; Qi H; Cui W; Zhang L; Fu X; He X; Liu M; Li PF; Yu T
    Signal Transduct Target Ther; 2023 Jan; 8(1):36. PubMed ID: 36646687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges.
    Luther DC; Lee YW; Nagaraj H; Scaletti F; Rotello VM
    Expert Opin Drug Deliv; 2018 Sep; 15(9):905-913. PubMed ID: 30169977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-editing applications of CRISPR-Cas9 to promote in vitro studies of Alzheimer's disease.
    Giau VV; Lee H; Shim KH; Bagyinszky E; An SSA
    Clin Interv Aging; 2018; 13():221-233. PubMed ID: 29445268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9 Delivery Potentials in Alzheimer's Disease Management: A Mini Review.
    Hanafy AS; Schoch S; Lamprecht A
    Pharmaceutics; 2020 Aug; 12(9):. PubMed ID: 32854251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in CRISPR/Cas9 Technology for in Vivo Translation.
    Çiçek YA; Luther DC; Kretzmann JA; Rotello VM
    Biol Pharm Bull; 2019; 42(3):304-311. PubMed ID: 30828060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR-based therapeutics: current challenges and future applications.
    Modell AE; Lim D; Nguyen TM; Sreekanth V; Choudhary A
    Trends Pharmacol Sci; 2022 Feb; 43(2):151-161. PubMed ID: 34952739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Gene Editing of Glia Maturation Factor in Microglia: a Novel Alzheimer's Disease Therapeutic Target.
    Raikwar SP; Thangavel R; Dubova I; Selvakumar GP; Ahmed ME; Kempuraj D; Zaheer SA; Iyer SS; Zaheer A
    Mol Neurobiol; 2019 Jan; 56(1):378-393. PubMed ID: 29704201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9 Genome Editing Approaches for Psychiatric Research.
    Gutiérrez-Rodríguez A; Cruz-Fuentes CS; Genis-Mendoza AD; Nicolini H
    Braz J Psychiatry; 2023 May; 45(2):137-145. PubMed ID: 36753615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenome editing by CRISPR/Cas9 in clinical settings: possibilities and challenges.
    Pei WD; Zhang Y; Yin TL; Yu Y
    Brief Funct Genomics; 2020 May; 19(3):215-228. PubMed ID: 31819946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.